Can You Get Flu, COVID, and RSV Vaccines at the Same Time?

Getting your flu, COVID-19, and RSV vaccines in a single visit is safe for most adults and is recommended by the CDC. Clinical trials and real-world data consistently show that co-administering these three respiratory vaccines produces immune responses that are largely comparable to getting each shot separately, with side-effect profiles that remain mild to moderate. The story gets more interesting when you look at the fine print of those trials, because “mostly comparable” is doing some work in that sentence.

What the Clinical Trials Found

The most direct evidence for the triple combination comes from a phase 3 trial that tested Moderna’s mRNA-based RSV vaccine (mRNA-1345) given alongside either a seasonal flu shot or a COVID-19 booster in adults aged 50 and older. The trial was split into two parts. Part A paired the RSV vaccine with a standard influenza shot; Part B paired it with a bivalent COVID-19 vaccine. In both cases, the reactogenicity profiles of the co-administered regimens were generally similar to the profiles when the vaccines were given alone, and no serious adverse events considered related to vaccination were reported through six to seven months of follow-up.¹

Separate trials have looked at other vaccine combinations. An RSV protein-based vaccine co-administered with high-dose flu vaccine in adults 65 and older demonstrated a noninferior immune response for both the flu and RSV components, meaning the antibody levels produced when the two were given together stayed within an acceptable range of what each vaccine produced on its own.² Another phase 3 trial of an adjuvanted RSV vaccine given with a quadrivalent flu shot met the noninferiority bar for three of the four flu strains tested.³ And co-administration of an adjuvanted RSV vaccine with a COVID-19 mRNA vaccine in adults 50 and older maintained what researchers called an acceptable safety profile, with most side effects being mild to moderate and lasting three days or fewer.⁴

Taken together, the pattern across these trials is consistent: giving two or three respiratory vaccines at the same visit does not create new safety problems. A narrative review summarizing the overall body of evidence concluded that there is no evidence non-live vaccines, including respiratory vaccines, interfere significantly with the immune responses to other vaccines, and that the CDC recommends co-administration of all age-appropriate vaccines at a single healthcare visit, including influenza, RSV, and COVID-19.⁵

The Small Dip in Antibody Levels

Safety is one question. Whether each vaccine works just as well when given alongside others is a slightly different one, and the answer is a qualified “almost.” In the Moderna trial, when the RSV vaccine was co-administered with the flu shot, the ratio of RSV-A neutralizing antibodies compared to the RSV-vaccine-alone group was about 0.81. When paired with the COVID-19 booster, that ratio was 0.80. Both met the study’s predefined threshold for noninferiority. The COVID-19 vaccine’s immune response was essentially unaffected, with antibody ratios for the ancestral strain and Omicron BA.1 landing at 0.96 and 1.00, respectively.⁶

In plain terms, the RSV antibody response dipped by roughly 20% when given alongside another vaccine, while the flu and COVID responses barely budged. That 20% dip sounds concerning, but it consistently fell within what the trials defined as an acceptable margin. The RSV vaccine still generated a strong immune response; it was just slightly less strong than getting the RSV shot on its own. Researchers noted that these differences were not expected to be clinically meaningful.⁵

There is one exception worth flagging. In one part of the Moderna trial, the seroresponse rate difference for RSV-A antibodies when the RSV vaccine was given with the flu shot did not technically meet the noninferiority criterion, even though the antibody ratio itself did. This is a statistical nuance: the overall antibody levels were acceptable, but the proportion of people who hit a certain threshold of immune response was slightly lower than the cutoff the trial had set in advance.¹ Similarly, a trial of an adjuvanted RSV vaccine given with a COVID-19 mRNA vaccine reported a marginal miss of the noninferiority criterion for the COVID-19 component, though the investigators judged this did not suggest clinically relevant interference.⁴

The honest interpretation: co-administration nudges certain antibody responses down slightly, and in a handful of statistical measures, that nudge brushes right up against the threshold researchers set ahead of time. But no trial found that co-administration produced a meaningfully weaker real-world protection. The effect is small enough that the convenience of a single visit far outweighs the marginal difference for most people.

What Side Effects to Expect

If you get two or three shots in one visit, you will probably feel it more than if you got just one. The most common local reaction across the trials was injection-site pain, reported by at least 20% of participants. The most common systemic reactions were fatigue, headache, muscle pain, and joint pain, also occurring in at least 20% of participants receiving co-administered vaccines.⁶ The vast majority of these were mild to moderate. When the RSV vaccine was paired with the COVID booster, the co-administration group had slightly higher rates of fatigue and muscle pain than the individual-vaccine groups, but the difference was small.¹

A study specifically looking at co-administered flu and COVID-19 mRNA vaccines found that side effects were expectedly higher in people who received both compared to those who got only the flu shot, which makes intuitive sense since mRNA vaccines tend to produce more noticeable reactions than traditional flu shots. But the cellular immune response to influenza was not notably different regardless of how the vaccines were given.⁷

The key takeaway on side effects: expect a rougher day or two after getting multiple shots compared to getting one. But “rougher” here means more fatigue and soreness, not a fundamentally different type of reaction. No serious adverse events were attributed to co-administration in any of the trials discussed above.

Real-World Safety Monitoring After Rollout

Clinical trials are designed under controlled conditions, so what happens once millions of people start getting these combinations in pharmacies and clinics? A recent analysis of the U.S. Vaccine Adverse Event Reporting System (VAERS) examined reports from people who received RSV plus COVID-19, RSV plus flu, or all three vaccines together. Among the triple-vaccination group, 194 reports were collected. Across all groups, more than 96% of reported events occurred within 30 days of vaccination, and the large majority, between roughly 86% and 89%, were classified as non-serious. The most commonly reported events were headache, fatigue, and injection-site pain.⁸

The analysis did flag some potential safety signals worth watching, including reports of dizziness, skin reactions, and gait disturbance. Among serious reports, signals for flu-like illness, stroke, and muscle weakness appeared across all groups, not just the triple-vaccination group. VAERS is a passive reporting system that captures raw signals rather than confirmed causal links, so these findings are a starting point for further investigation rather than proof of harm. Still, the overall picture from real-world reporting aligns with the clinical trial data: most reactions are mild and self-resolving, and the serious events are rare.⁸

Why Your Immune System Can Handle Multiple Vaccines

A common worry is that getting three vaccines at once will “overwhelm” the immune system. This concern is understandable but not supported by how the immune system actually works. Your body encounters thousands of new foreign substances every day, from the bacteria on your food to the viruses floating in the air of a crowded room. The immune system’s capacity to handle simultaneous challenges is enormous. A widely cited analysis estimated that an infant’s immune system could theoretically respond to roughly 10,000 vaccines at once, and that 11 simultaneous vaccines would occupy about 0.1% of the available immune capacity. Because immune cells are constantly being replenished, no vaccine ever truly “uses up” part of the system.⁹

That estimate was made in the context of childhood vaccines, but the underlying principle holds for adults. Three respiratory vaccines contain a small number of antigens compared to what your immune system already processes daily. The minor dips in antibody responses described earlier are not a sign of immune exhaustion. They likely reflect competition for immune resources at the injection site rather than any systemic depletion.

Same Arm or Different Arms

If you are getting two or three injections, does it matter which arm each goes into? There is some evidence from preclinical work that the location and timing of vaccine delivery matters more than people assume. Research in mice found that vaccine antigens and their immune-boosting components need to be delivered at the same site and at the same time to maximize the immune response. Separating them by location or even by 24 hours significantly reduced the effect.¹⁰ This speaks to how individual vaccine components interact with each other, not to whether different vaccines can share an arm.

For people getting multiple distinct vaccines in one visit, the practical guidance is straightforward: each vaccine should go into a different injection site, ideally at least an inch apart. Many providers will give one in each arm, and if there is a third, put it in the same arm as the one you expect will cause the least soreness. There is no firm rule here, and the data on co-administered flu and COVID vaccines showed that giving them in different arms tended to produce slightly better antibody responses for the flu component compared to putting them in the same arm.⁷ When in doubt, different arms is the simpler choice.

Why One Visit Matters More Than You Think

The practical argument for co-administration goes beyond personal convenience. Requiring multiple visits for multiple vaccines is one of the most reliable ways to ensure some of those vaccines never get given. Adults are notoriously bad at coming back for follow-up appointments. Co-administration of pediatric and travel vaccines has a well-established track record of improving coverage and saving costs, but the practice has been far less routine for adult respiratory vaccines.¹¹

Every additional visit adds friction: scheduling, travel, time off work, the simple inertia of putting something off. For older adults at highest risk from all three respiratory viruses, consolidating protection into a single fall appointment removes a significant barrier. This is part of why the CDC’s recommendation to give all age-appropriate vaccines at a single visit is framed as a public health priority, not just a matter of individual preference.⁵

What Makes People Hesitant

Despite the safety data, plenty of people are uneasy about getting multiple vaccines at once. A scoping review of qualitative research on attitudes toward vaccine co-administration found that acceptance of getting COVID-19 and flu vaccines together varied dramatically by country, ranging from about 23% in Italy to roughly 80% in Canada. The factors that predicted acceptance included a healthcare provider’s recommendation, previous experience with co-administration, trust in available information, and a personal sense of control over the decision.¹²

Interestingly, many people who did not get vaccines together reported practical reasons rather than safety fears: the COVID vaccine became available before flu season started, they were not offered both at the same appointment, or they simply did not know co-administration was an option. This suggests the gap between evidence and uptake is partly a logistics problem, not just a trust problem. People who have done it before tend to be comfortable doing it again. Research with participants in a randomized trial exploring co-administration of multiple vaccines found that personal preference about the number of injections mattered to participants, and that clinical staff recognized practical adjustments would be needed for routine delivery.¹³

Special Situations Worth Knowing About

Most of the clinical trial data on triple co-administration has been generated in adults aged 50 and older, which makes sense since this group faces the highest risk from RSV, flu, and COVID-19 simultaneously. The Moderna trial specifically enrolled adults 50 and older and found the co-administered regimens had acceptable safety profiles with mostly noninferior immune responses in this age group.⁶

For younger healthy adults, the flu-COVID co-administration data is robust, and the general principle that non-live vaccines can be given simultaneously applies. One trial that compared concurrent flu and COVID vaccination against staggered doses in a general adult population found that the side effects were mild and similar between groups, though COVID-19 antibody levels were somewhat lower in the co-administration group compared to giving the COVID shot alone. The investigators noted the side-effect profile was reassuring even if the immune response showed some blunting.¹⁴

Pregnant people represent a unique case. RSV vaccination during pregnancy is a relatively new intervention, and safety surveillance during the early post-approval period has tracked outcomes in pregnancies where the RSV vaccine was given alongside other vaccines. Both RSV-vaccinated and comparison pregnancies in that surveillance could receive multiple vaccines, so real-world data on co-administration in pregnancy is being collected, though dedicated efficacy trials of the triple combination in pregnancy have not been published.¹⁵ If you are pregnant and considering the RSV vaccine alongside other immunizations, discussing timing with your provider is worth the conversation, since the data here is thinner than for older adults.

For children, the landscape is different. Kids do not currently receive an RSV vaccine in the traditional sense; instead, infants at risk typically receive a monoclonal antibody (nirsevimab), which is a passive immunization rather than a vaccine. The question of co-administering flu, COVID, and RSV vaccines simultaneously is primarily an adult concern, particularly for those 60 and older who are eligible for all three.

When Spacing Them Out Might Make Sense

Even though the data supports getting everything at once, there are situations where a person might reasonably choose to spread their vaccines out. If you have had unusually strong reactions to a particular vaccine in the past, separating your shots by a couple of weeks makes it easier to identify which one is causing problems if something goes wrong. People with certain autoimmune conditions or those on immunosuppressive medications sometimes prefer to stagger vaccinations so they can monitor for flares, though this is a personal risk-comfort calculation rather than a strict medical requirement.

The trade-off is real: spacing them out means you are unprotected against one or two of these viruses for a longer window during respiratory season. If you are 70 and flu, COVID, and RSV are all circulating in your community, the theoretical benefit of slightly higher RSV antibodies from getting that vaccine alone is weighed against the practical risk of catching one of the other two while you wait for your next appointment. For most people at high risk, getting protected against all three as soon as possible is the stronger play.